公开(公告)号：WO2015160597A1

公开(公告)日：2015-10-22

申请号：PCT/US2015/024965

申请日：2015-04-08

Applicant: TRUSTEES OF BOSTON UNIVERSITY

Inventor： REINHARD, Bjoern Markus ,  GUMMULURU, Suryaram

IPC: A61K9/127 ,  A61B5/055

CPC classification number: A61K9/5123 ,  A61B5/055 ,  A61K9/127 ,  A61K9/1271 ,  A61K9/1272 ,  A61K9/5115 ,  A61K9/5192 ,  A61K47/543 ,  A61K47/61 ,  A61K47/6911 ,  A61K47/6923 ,  A61K47/6929 ,  B82Y5/00 ,  G01N33/5005

Abstract: Embodiments disclosed herein relates to ganglioside GM3-containing mixed lipids nanoparticles having an overall size between 60-100 nm, the making thereof and the uses. The nanoparticles selectively targeted to CD169+ expressing cells such as dendritic cells and macrophage. The nanoparticles are endocytosed by the CD169+ expressing cells.

Abstract translation: 本文公开的实施方案涉及总体尺寸在60-100nm之间的含神经节苷脂GM3的混合脂质纳米颗粒，其制备和用途。 纳米颗粒选择性靶向CD169 +表达细胞，如树突状细胞和巨噬细胞。 纳米颗粒被CD169 +表达细胞内吞。

公开(公告)号：WO2014197329A1

公开(公告)日：2014-12-11

申请号：PCT/US2014/040333

申请日：2014-05-30

Applicant: TRUSTEES OF BOSTON UNIVERSITY

Inventor： GRINSTAFF, Mark ,  MELLER, Amit ,  HERSEY, Joseph ,  SQUIRES, Allison

IPC: B32B9/00 ,  B32B3/24 ,  C12Q1/68

CPC classification number: G01N33/48721 ,  B05D1/007 ,  C08J7/047 ,  C08J2309/02 ,  C08J2477/02 ,  C12Q1/6825 ,  G01N27/44747 ,  G01N27/44791 ,  C12Q2565/631

Abstract: Provided herein are compositions, compounds, processes, and methods of use of 3D porous coating(s) on or near a nanopore(s) for analysis or detection of charged polymers such as nucleic acids, proteins, protein-nucleic acid complexes, small molecule-biological complexes, polymer-biological complexes, and/or polyelectrolytes.

Abstract translation: 本文提供了用于分析或检测带电聚合物如核酸，蛋白质，蛋白质 - 核酸复合物，小分子的纳米孔上或附近的三维多孔涂层的组合物，化合物，方法和方法 生物复合物，聚合物 - 生物复合物和/或聚电解质。

公开(公告)号：WO2014186430A1

公开(公告)日：2014-11-20

申请号：PCT/US2014/037946

申请日：2014-05-14

Applicant: TRUSTEES OF BOSTON UNIVERSITY

Inventor： KIM, Joshua Jaeyun ,  WONG, Joyce Yun-Wei

IPC: C12N11/12

CPC classification number: C12N5/0698 ,  A61L27/3804 ,  A61L27/3808 ,  A61L27/3813 ,  A61L27/3826 ,  A61L27/3834 ,  A61L27/3891 ,  A61L27/507 ,  A61L27/60 ,  C12N5/0062 ,  C12N5/0068 ,  C12N2533/74 ,  C12N2533/78 ,  C12N2535/00 ,  C12N2539/00 ,  G01N33/5082

Abstract: The present disclosure relates generally to the fields of tissue engineering and regenerative medicine. More particularly, the present disclosure generally relates to systems, methods, compositions and kits to rapidly fabricate functionalized three-dimensional tissues from multiple stacks of cell sheets using enzyme-digestible hydrogel substrates as supports for the cell sheets. Methods to generate the multi-layered cell constructs comprise contacting a cell-sheet on one digestable substrate with another cell-sheet on a different digestible substrate, enzymatically digesting with a first enzyme to remove the first substrate and subsequently adding repeating the steps to add another cell-sheet on same digestable substrate to form a multi-layered cell construct as disclosed herein. Additional aspects relate to using the multi-layered cell constructs for therapeutic use, research and in screening assays.

Abstract translation: 本公开一般涉及组织工程和再生医学领域。 更具体地说，本公开内容通常涉及使用可酶消化的水凝胶基质作为细胞片的支持体从多个细胞片层叠快速制造功能化的三维组织的系统，方法，组合物和试剂盒。 产生多层细胞构建体的方法包括将一个可消化底物上的细胞片与不同可消化底物上的另一种细胞片接触，用第一种酶酶消化以除去第一种底物，随后添加重复步骤以添加另一种 细胞片在相同的可消化底物上以形成如本文公开的多层细胞构建体。 另外的方面涉及使用多层细胞构建体用于治疗用途，研究和筛选测定。

公开(公告)号：WO2014116962A1

公开(公告)日：2014-07-31

申请号：PCT/US2014/012968

申请日：2014-01-24

Applicant: TRUSTEES OF BOSTON UNIVERSITY ,  DANA-FARBER CANCER INSTITUTE, INC.

Inventor： BEELER, Aaron Beaty ,  PORCO, John A. Jr. ,  INGHAM, Oscar J. ,  BRADNER, James E.

IPC: A61K31/16 ,  A61K31/4192 ,  A61P35/00

CPC classification number: A61K31/4192 ,  A61K45/06 ,  C07D249/06

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that benefit from inhibition of HDAC8 activity

Abstract translation: 本文描述了含有这种化合物的化合物和药物组合物，其抑制组蛋白脱乙酰酶8（HDAC8）的活性。 本文还描述了使用这样的HDAC8抑制剂单独和与其它化合物组合用于治疗受益于HDAC8活性抑制的疾病或病症的方法

公开(公告)号：WO2014031612A1

公开(公告)日：2014-02-27

申请号：PCT/US2013/055749

申请日：2013-08-20

Applicant: BOSTON MEDICAL CENTER CORPORATION

Inventor： MONTANO, Monty

IPC: A61K35/12 ,  C12N5/22

CPC classification number: G01N33/5061 ,  A61K31/436 ,  A61K35/12 ,  C12N5/0658 ,  C12N2501/155 ,  G01N33/5073 ,  G16H15/00 ,  G16H50/20 ,  Y02A90/26

Abstract: Disclosed herein are novel assays, systems and kits for generating a personalized or stratified diagnostic report, e.g., to facilitate selection of an appropriate treatment of a musculoskeletal disease or disorder in a subject. The assays and systems are based on detecting and/or measuring in vitro anabolic responses of musculoskeletal cells or precursor cells thereof to a panel of test compositions (e.g., test compositions each comprising at least one agent selected to maintain and/or increase muscle and/or bone growth), and ranking the ability of each test composition to stimulate muscle and bone growth. The resultant ranks of the test compositions can then be used to identify, select, and/or optimize a treatment regimen for the subject who is determined to have, or have a risk, a musculoskeletal disease or disorder. Methods for treating and/or preventing a musculoskeletal disease or disorder are also provided herein.

Abstract translation: 本文公开了用于产生个性化或分层诊断报告的新型测定，系统和试剂盒，例如有助于选择受试者中肌肉骨骼疾病或病症的适当治疗。 测定和系统基于检测和/或测量肌肉骨骼细胞或其前体细胞的体外合成代谢反应到一组测试组合物（例如，每种测试组合物包含至少一种选择用于维持和/或增加肌肉和/ 或骨生长），并且排列每个测试组合物刺激肌肉和骨骼生长的能力。 然后，所得到的测试组合物的级别可用于鉴定，选择和/或优化被确定具有或具有肌肉骨骼疾病或病症风险的受试者的治疗方案。 本文还提供了治疗和/或预防肌肉骨骼疾病或病症的方法。

公开(公告)号：WO2013112467A1

公开(公告)日：2013-08-01

申请号：PCT/US2013/022537

申请日：2013-01-22

Applicant: TRUSTEES OF BOSTON UNIVERSITY

Inventor： RUIZ-OPAZO, Nelson ,  HERRERA, Victoria, L.M.

IPC: C07K16/28

CPC classification number: C07K16/2863 ,  A61K9/0019 ,  A61K49/0004 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2869 ,  C07K2317/34 ,  C07K2317/62 ,  C07K2317/73 ,  C07K2317/76

Abstract: Provided herein are novel compositions comprising DEspR-specific antagonists and agonists, and methods of their use in a variety of therapeutic applications. The compositions comprising the DEspR-specific anatgonists and agonists described herein are useful in therapeutic, diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo-non invasive imaging and/or assessments.

Abstract translation: 本文提供了包含DEspR特异性拮抗剂和激动剂的新型组合物，以及其用于各种治疗应用的方法。 包含本文所述的DEspR特异性吞咽者和激动剂的组合物可用于治疗，诊断和成像方法，例如血管发生的DEspR靶向分子成像，以及伴随诊断和/或体内非侵入性成像和/或评估。

公开(公告)号：WO2013059295A2

公开(公告)日：2013-04-25

申请号：PCT/US2012/060582

申请日：2012-10-17

Applicant: TRUSTEES OF BOSTON UNIVERSITY ,  THE BRIGHAM AND WOMEN'S HOSPITAL, INC. ,  GRINSTAFF, Mark, W. ,  COLBY, Aaron, H. ,  COLSON, Yolonda

Inventor： GRINSTAFF, Mark, W. ,  COLBY, Aaron, H. ,  COLSON, Yolonda

IPC: A61K9/16 ,  A61K9/14 ,  A61K47/48 ,  A61K47/30 ,  A61K31/337 ,  A61K31/357 ,  A61P35/00

CPC classification number: A61K9/1641 ,  A61K9/5138 ,  A61K31/337 ,  A61K31/352 ,  A61K31/519 ,  A61K47/555 ,  A61K49/0054

公开(公告)号：WO2013013038A2

公开(公告)日：2013-01-24

申请号：PCT/US2012/047398

申请日：2012-07-19

Applicant: TRUSTEES OF BOSTON UNIVERSITY ,  GRINSTAFF, Mark W. ,  WOLINSKY, Jesse ,  YOHE, Stefan ,  KAPLAN, Jonah Andrew ,  FALDE, Eric John ,  HERSEY, Joseph Steven

Inventor： GRINSTAFF, Mark W. ,  WOLINSKY, Jesse ,  YOHE, Stefan ,  KAPLAN, Jonah Andrew ,  FALDE, Eric John ,  HERSEY, Joseph Steven

IPC: A61K47/48 ,  A61K47/30 ,  A61K9/70 ,  A61K31/337 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61L31/148 ,  A61K9/0024 ,  A61K9/70 ,  A61K31/337 ,  A61K31/4745 ,  A61K41/0028 ,  A61L27/18 ,  A61L27/54 ,  A61L27/56 ,  A61L27/58 ,  A61L31/06 ,  A61L31/146 ,  A61L31/16 ,  A61L2300/216 ,  A61L2300/416 ,  A61L2300/602 ,  A61L2300/802 ,  C08L67/04

Abstract: Provided herein are 3-dimensional drug-eluting materials comprising biodegradable polymer(s), one or more bioactive agents and entrapped air. Various embodiments of the methods and compositions described herein are based, in part, on the discovery of hydrophobic doping agents that can be used in the manufacture of polymeric drug delivery compositions that permit the encapsulation of air, thereby permitting tunable drug release via controlled air removal. Such compositions are particularly useful for delivering therapeutically effective doses of one or more bioactive agents to a subject over an extended period of time (e.g., days, weeks, or months).

Abstract translation: 本文提供了包含可生物降解的聚合物，一种或多种生物活性剂和捕获的空气的三维药物洗脱物质。 本文描述的方法和组合物的各种实施方案部分地基于可用于制造可以包封空气的聚合物药物递送组合物的疏水性掺杂剂的发现，从而通过可控的空气去除来允许可调节的药物释放 。 这样的组合物特别可用于在长时间（例如，几天，几周或几个月）内向受试者递送治疗有效剂量的一种或多种生物活性剂。

公开(公告)号：WO2012103337A3

公开(公告)日：2012-08-02

申请号：PCT/US2012/022727

申请日：2012-01-26

Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC. ,  BLUMBERG, Richard ,  KASER, Arthur ,  MEDIZINISCHE UNIVERSITAT INNSBRUCK

Inventor： BLUMBERG, Richard ,  KASER, Arthur

IPC: C12Q1/68 ,  C12Q1/04 ,  G01N33/68 ,  C07K1/14 ,  G01N33/569

Abstract: Provided herein are MiIP-Seq assays and methods for detecting and/or identifying an immune-stimulating microbe in a patient sample. Also provided herein are methods for diagnosing an infectious disease or identifying a previously uncharacterized microbe in a patient sample. The methods and assays described herein are advantageous over existing methods in that they (i) do not require a culture step for microbe expansion, (ii) are not specific for a particular microbe and can be used to identify a previously uncharacterized microbe, and (iii) permits rapid processing due to the lack of a microbe culture step.

公开(公告)号：WO2011072086A9

公开(公告)日：2011-06-16

申请号：PCT/US2010/059584

申请日：2010-12-08

Applicant: HEMAQUEST PHARMACEUTICALS, INC. ,  TRUSTEES OF BOSTON UNIVERSITY ,  PERRINE, Susan ,  BERENSON, Ronald, J. ,  FALLER, Douglas, V.

Inventor： PERRINE, Susan ,  BERENSON, Ronald, J. ,  FALLER, Douglas, V.

IPC: A01N37/10

Abstract: Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor.. Treatment can be continued for at least two weeks.